While our initial discovery laid the foundation for the development of clinical trials evaluating combined PI3K and AR pathway inhibition in prostate cancer, our current work highlights the diversity of responsiveness among prostate cancers harboring loss of PTEN and further defines mechanisms of response and resistance. This evidence concerns the gene AR and prostate cancer.